Ultrasound-detected hepatic steatosis in psoriatic disease: prevalence, cardiometabolic correlates, and biochemical discordance

For millions of people, a skin condition known as psoriasis is more than just a rash. It is a sign that the body's immune system is in a state of constant, low-level alarm. This inflammation does not stay confined to the skin; it travels through the bloodstream, affecting the heart, blood vessels, and the liver. In recent years, doctors have recognized that people with this disease often carry a hidden burden of metabolic trouble, such as excess weight around the middle, high blood sugar, and fatty deposits in the liver. The liver, a vital organ that filters the blood and processes nutrients, can become clogged with fat, a condition called hepatic steatosis. While this fat accumulation is often silent, it can eventually lead to serious liver damage. The challenge for doctors has been figuring out who is at risk. Standard blood tests that look for liver injury often come back normal even when fat is present, creating a blind spot in routine care. This leaves a critical question: in a population already fighting inflammation, how common is this silent liver fat, what actually causes it, and how can we find it when the usual tests fail?

A team of researchers at a major hospital in Spain set out to answer these questions by looking directly at the livers of nearly six hundred adults living with psoriasis or a related joint condition called psoriatic arthritis. Instead of relying on blood work alone, they used abdominal ultrasound, a safe imaging technique that uses sound waves to create pictures of the inside of the body. This approach allowed them to see fat deposits directly, regardless of whether the patients had any symptoms or abnormal blood results. The study included a diverse group of patients, some with mild skin involvement and others with severe disease, some with joint pain and others without. By examining this large, real-world group, the researchers hoped to map out exactly who was carrying this extra liver fat and why.

The results revealed that the problem was far more common than many might expect. Among the patients who had an ultrasound, nearly one in four showed signs of fatty liver. This finding was significant because it confirmed that liver fat is a frequent companion to psoriatic disease, affecting a substantial portion of the population. However, the study also clarified what was driving this condition. When the researchers analyzed the data, they found that the severity of the skin rash or the presence of painful joints did not predict who had fatty liver. A patient with a mild rash was just as likely to have liver fat as someone with a severe, widespread outbreak. Similarly, having psoriatic arthritis did not increase the risk compared to having skin psoriasis alone.

Instead, the strongest signals came from the body's metabolic health. The researchers found that the amount of fat stored around the waist was the most consistent predictor of liver fat. For every ten centimeters increase in waist circumference, the likelihood of having fatty liver rose significantly. This association held true even after accounting for age, sex, alcohol consumption, and other metabolic factors like high blood pressure or diabetes. The study also highlighted the role of alcohol; patients who currently drank alcohol were much more likely to have fatty liver than those who did not. These findings suggest that for people with psoriasis, the risk of fatty liver is tied more closely to central obesity and metabolic health than to the intensity of their skin or joint disease.

Perhaps the most important discovery of the study concerned the reliability of standard blood tests. In clinical practice, doctors often use levels of enzymes called aminotransferases to screen for liver problems. If these enzymes are normal, the liver is usually assumed to be healthy. However, this study showed that this assumption can be misleading. Among the patients whose aminotransferase levels were perfectly normal, nearly one in ten still had fatty liver visible on ultrasound. This means that a "normal" blood test result does not guarantee the absence of liver fat. The researchers then looked for a better clue within the blood work and found a promising candidate in another enzyme called gamma-glutamyl transferase, or GGT.

In the group of patients with normal aminotransferases, those who had elevated GGT levels were overwhelmingly likely to have fatty liver. The test was highly specific, meaning that if a patient had high GGT, it was a very strong indicator that liver fat was present. While a normal GGT level could not completely rule out the condition, an elevated level served as a powerful warning sign. This suggests that for patients with psoriasis who have normal standard liver enzymes, checking GGT could help identify those who need further investigation. The study did not prove that high GGT causes the liver fat, but it demonstrated that the two are closely linked in this population, offering a practical tool for doctors to spot at-risk patients who would otherwise be missed.

The researchers also examined how these patients fit into modern categories of liver disease. Most of the individuals with fatty liver also met the criteria for a condition driven by metabolic dysfunction, such as insulin resistance or high triglycerides. A smaller number had liver fat linked to alcohol consumption. The study noted that because the data on alcohol intake was not always complete, the researchers could not definitively classify every case, but the pattern was clear: metabolic health was the dominant factor. The team also considered whether the medications used to treat psoriasis, such as methotrexate, might be the cause. While they could not fully separate the effects of specific drugs from the disease itself, their analysis suggested that the metabolic factors were the primary drivers, rather than the treatment.

This work provides a clearer picture of the hidden risks facing people with psoriatic disease. It moves the focus away from the visible symptoms of skin and joints and toward the invisible metabolic changes happening inside the body. By showing that fatty liver is common and often undetected by standard tests, the study argues for a more thorough approach to care. It suggests that measuring waist circumference and paying attention to GGT levels could help doctors catch liver problems early, before they cause irreversible damage. The findings do not offer a cure, but they offer a better map for navigating the complex health landscape of psoriasis, ensuring that the liver is not overlooked in the fight against this systemic inflammatory condition.